Sant Joan de Deu Health Park
If you are the contact person for this centre and you wish to make any changes, please contact us.
Miguel Servet Senior Researcher at the Teaching, Research and Innovation Unit of the Parc Sanitari Sant Joan de Déu, member of the Department of Psychiatry at Warneford Hospital-University of Oxford (UK) and member of Spain's Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP)
Psychiatrist and principal researcher at Parc Sanitari Sant Joan de Deu and Fundació de Recerca Sant Joan de Deu and secretary of the Spanish Society of Psychedelic Medicine
Psychiatrist, therapist and researcher at Parc Sanitari Sant Joan de Déu and Institut de Recerca Sant Joan de Déu, ANIMA group
Dimethyltryptamine (DMT) is responsible for the psychedelic effects of ayahuasca. According to the results of a phase IIa clinical trial published in Nature Medicine, this molecule improved depressive symptoms in adults with depression after one dose. The trial included 34 people, 17 of whom received intravenous DMT. This second group showed greater improvements in depressive symptoms than the control group. After two weeks, in the second part of the trial, DMT was administered to all participants and the antidepressant effects lasted for three months. Adverse effects were mainly pain at the injection site, nausea and transient anxiety.
Research involving more than 200 patients with depression, whose symptoms had not improved after NHS talk therapy shows that those who took part in eight group sessions of mindfulness-based cognitive therapy saw their depressive symptoms reduced, compared with those who received treatment as usual. The study is published in The Lancet Psychiatry.
A dose of psilocybin—a hallucinogenic substance—administered to groups of 3 or 4 people suffering from cancer and depression may help reduce their depressive symptoms, according to a clinical trial conducted in the United States. The study involved 30 patients who also received individual and group therapeutic support. In another article, also published in the journal Cancer, the authors examine how the study participants perceived the therapy.